| Trial ID: | L5414 |
| Source ID: | NCT05593549
|
| Associated Drug: |
Trehalose
|
| Title: |
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Healthy Aging
|
| Interventions: |
DRUG: Trehalose|DRUG: Placebo
|
| Outcome Measures: |
Primary: Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis, Cutaneous microvascular function measured via laser Doppler flowmetry coupled with intradermal microdialysis of non-specific nitric oxide synthase inhibitor, L-NAME, 2 weeks|Autophagic Flux Protein Expression, Autophagic Flux protein expression in Peripheral Blood Mononuclear Cells (PBMC) will be measured via exogenous treatment of PBMCs with a lysosomal inhibitor and then expression of autophagic markers will be assessed via Western Blot., 2 weeks | Secondary: Blood Pressure, Brachial Blood Pressure, 2 weeks
|
| Sponsor/Collaborators: |
Sponsor: Medical College of Wisconsin
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2023-01-01
|
| Completion Date: |
2029-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-05-31
|
| Locations: |
Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05593549
|
